Title |
An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management
|
---|---|
Published in |
BMC Pregnancy and Childbirth, February 2013
|
DOI | 10.1186/1471-2393-13-34 |
Pubmed ID | |
Authors |
Jeffrey Michael Smith, Richard F Lowe, Judith Fullerton, Sheena M Currie, Laura Harris, Erica Felker-Kantor |
Abstract |
Pre-eclampsia/eclampsia is one of the most common causes of maternal and perinatal morbidity and mortality in low and middle income countries. Magnesium sulfate is the drug of choice for prevention of seizures as part of comprehensive management of the disease. Despite the compelling evidence for the effectiveness of magnesium sulfate, concern has been expressed about its safety and potential for toxicity, particularly among providers in low- and middle-income countries. The purpose of this review was to determine whether the literature published in these global settings supports the concerns about the safety of use of magnesium sulfate. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 33% |
United Kingdom | 1 | 11% |
Colombia | 1 | 11% |
Unknown | 4 | 44% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 8 | 89% |
Scientists | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Colombia | 1 | <1% |
Malaysia | 1 | <1% |
Ethiopia | 1 | <1% |
Brazil | 1 | <1% |
New Zealand | 1 | <1% |
Egypt | 1 | <1% |
Unknown | 221 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 42 | 19% |
Student > Bachelor | 34 | 15% |
Student > Postgraduate | 24 | 11% |
Researcher | 14 | 6% |
Other | 13 | 6% |
Other | 45 | 20% |
Unknown | 55 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 108 | 48% |
Nursing and Health Professions | 12 | 5% |
Psychology | 11 | 5% |
Social Sciences | 7 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 2% |
Other | 24 | 11% |
Unknown | 60 | 26% |